Loyal Raises $45M in Series B Financing
March 25, 2024, 9:49 am
Loyal, a biotech company in San Francisco, has secured $45 million in Series B funding to develop drugs for dogs. Led by CEO Celine Halioua, the company aims to extend the lifespan of dogs by targeting the mechanisms of aging. With three drugs in development, Loyal is on track for a product launch in early 2025 pending FDA approval. Investors like Bain Capital Ventures and Khosla Ventures are backing Loyal's mission to give dogs longer, healthier lives.